Author

H. Montazeri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Evolutionary Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:organoid / primary culture· 1 Approach:statistical model· 1

Frequent Co-Authors

N. Beerenwinkel· 2 shared A. Chavez· 1 shared A. Dahmani· 1 shared A. F. Kratz· 1 shared A. K. Aditham· 1 shared B. Culbertson· 1 shared C. Ercan· 1 shared C. K. Ng· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersEvolutionary Biology

N. Beerenwinkel

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Functional Landscape of SARS-CoV-2 3CL Protease

S. Iketani, S. J. Hong, J. Sheng, F. Bahari, B. Culbertson, F. F. Atanaki, A. K. Aditham, A. F. Kratz, M. I. Luck, R. Tian, S. P. Goff, H. Montazeri, Y. Sabo, D. D. Ho, A. Chavez

This study maps the functional landscape of SARS-CoV-2 3CL protease by profiling all single mutants and identifies resistance mutations to nirmatrelvir.

bioRxiv · Jun 23, 2022 · PreprintMicrobiology

Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C

S. Posada-Cespedes, G. Van Zyl, H. Montazeri, J. Kuipers, S.-Y. Rhee, R. Kouyos, H. F. Günthard, N. Beerenwinkel

This paper compares mutational pathways to lopinavir resistance in HIV-1 subtypes B and C using a probabilistic model, finding distinct initial mutations and diverse evolutionary pathways.

bioRxiv · Sep 25, 2020Evolutionary Biology

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

G. Bianco, M. Coto Llerena, J. Gallon, S. Taha-Mehlitz, V. Kancherla, M. Konantz, S. Srivatsa, H. Montazeri, F. Panebianco, M. De Menna, V. Paradiso, C. Ercan, A. Dahmani, E. Montaudon, N. Beerenwinkel, , S. Piscuoglio

This study identifies GATA3 and MDM2 as synthetic lethal in ER-positive breast cancers, showing MDM2 inhibition can target GATA3-deficient tumors via the PI3K/Akt/mTOR pathway.

bioRxiv · May 18, 2020Cancer Biology